Results 161 to 170 of about 269,940 (298)

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell‐Targeted Therapies

Arthritis &Rheumatology, Accepted Article.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Successful treatment of severe systemic lupus erythematosus with anifrolumab: a single-center observational study. [PDF]

Reumatologia
Wisłowska M, Szczęsny P, Wroński J, Bonek K.   +3 more
europepmc   +1 more source

National Mortality Databases to Assess Disease Burden in Systemic Autoimmune Diseases: A Valuable Resource, But with Limitations

Arthritis &Rheumatology, Accepted Article.
Disease‐specific mortality statistics are useful measures of disease burden. Population‐based studies from a few United States counties have reported mortality in systemic autoimmune diseases (SAID). However, due to substantial differences in the population structure of these counties as well as relatively small numbers of SAID deaths in these counties,
Ram Raj Singh
wiley   +1 more source

Anifrolumab for refractory chilblain lupus erythematosus. [PDF]

Int J Womens Dermatol
Bulosan H, Kalus A, Thomason J, Cogen AL.   +3 more
europepmc   +1 more source

The efficacy of Telitacicept in Childhood‐onset Systemic Lupus Erythematosus: a prospective multi‐center cohort study with IPTW‐adjusted comparison to a historical control group treated with Belimumab

Arthritis &Rheumatology, Accepted Article.
Objective The therapeutic effects of Telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with Belimumab combined with SoC. Methods We performed a prospective cohort study across 7 tertiary hospitals in China, enrolling patients ...
Chong Luo, Shu Su, Jingyue Liu, Junyu Lin, Jin Song, Zongwen Chen, Yuanyuan Peng, Lijun Jiang, Meng Jia, Li Wang, Xinhui Jiang, Wei Zhang, Zanhua Rong, Bo zhao, Yajun Wang, Xuemei Tang   +15 more
wiley   +1 more source

HLA‐DQA1*01:02 is associated with antibody multi‐reactivity with citrulline‐containing type II collagen epitopes while HLA‐DRB1*04:01 is associated with more private antibody reactivity with citrulline‐containing IgG epitopes in rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Objective Anti‐citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) can be promiscuous, with cross‐reactive binding to many antigens containing short motifs, or private with little cross‐reactivity. Also, ACPA reactivity patterns differ among RA patients, including for motif‐containing epitopes in important self‐antigens like collagen ...
S. Janna Bashar, Courtney B. Myhr, Adam H. Titi, Zihao Zheng, Miriam A. Shelef   +4 more
wiley   +1 more source

A Sonidegib Experience in the Treatment of Basal Cell Carcinoma with Systemic Lupus Erythematosus: A Case Report. [PDF]

Clin Cosmet Investig Dermatol
Shi L, Liu B, Gao P, Cao X, Wan C.
europepmc   +1 more source

Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?

Arthritis &Rheumatology, Accepted Article.
Objective Lupus nephritis (LN) is characterized by a variable disease course, necessitating continuous monitoring. There is an urgent need to identify non‐invasive biomarkers. By reviewing and critically assessing the quality of existing studies on LN biomarkers correlating with histopathology, we here explore the challenges in promoting their use in ...
Valentina Querin, Leonardo Palazzo, Agnes B. Fogo, Mark Haas, David R. W. Jayne, Liz Lightstone, Brad H. Rovin, Surya V. Seshan, Augusto Vaglio, Ioannis Parodis, Ingeborg M. Bajema, The LN classification steering committee   +11 more
wiley   +1 more source

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

, 2020
Bathon, J., Breedveld, F., Burmester, G., Bykerk, V., Crofford, L., Cronstein, B., Dougados, M., Furst, D., Kalden, J., Mariette, X., Mease, P., Melchers, F., Rosenbaum, J., Sieper, J., Smolen, J., Weinblatt, M., Winthrop, K.   +16 more
core   +1 more source